FOXO4-DRI and Cancer: What Does the Research Show?
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

FOXO4-DRI is an experimental peptide being studied for its ability to eliminate some senescent cells. These are cells that have stopped dividing but remain biologically active. The cancer research is interesting, but the evidence needs careful interpretation. The original 2017 Cell study investigated the interaction between FOXO4 and p53, proteins involved in cellular stress responses. In laboratory experiments, FOXO4-DRI promoted the death of certain senescent cells. Mouse experiments also reported improvements in selected measures of chemotherapy-related damage and age-related decline. This was preclinical research, not proof of cancer treatment in people. In 2021, researchers publishing in JCI Insight studied non-small cell lung cancer models. They found that radiation-induced, senescence-like fibroblasts surrounding tumors could help nearby cancer cells resist radiation. In the relevant mouse comparisons, adding FOXO4-DRI to radiation reduced tumor volume and weight compared with radiation in the presence of those senescence-like fibroblasts. The proposed benefit involved changing the tumor's surroundings. The study did not establish that FOXO4-DRI alone reliably shrinks established tumors, or that it prevents cancer recurrence in patients. A 2025 Nature Communications study added molecular detail. It mapped how FOXO4-DRI binds to a region of p53 called the transactivation domain, particularly TAD2. Understanding that interaction can guide drug development. A molecular binding result does not establish clinical effectiveness or safety. Cleara Biotech is developing a distinct, optimized candidate called CL04183 for cancers involving impaired p53 signaling. Company researchers described a planned phase-one study in a 2026 conference abstract. Results or development plans for CL04183 should not be presented as evidence for the original FOXO4-DRI peptide. Our November 5, 2026 searches of ClinicalTrials.gov found no matching registered studies under FOXO4-DRI or the related candidate names checked. The studies discussed here do not establish a safe human dose or demonstrate cancer-treatment benefit in people. Senescence is context-dependent, and removing these cells is not automatically beneficial in every tissue or cancer. FOXO4-DRI remains a research subject, not a substitute for established cancer care. Anyone considering experimental cancer treatment should discuss legitimate clinical-trial options with their oncology team.

END CARD
Preclinical research is not established cancer care. Full sources and limitations accompany this film.

SOURCES
[1] Baar et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
https://pubmed.ncbi.nlm.nih.gov/28340339/
Primary cell and mouse study

[2] Meng et al. (2021). Targeting senescence-like fibroblasts radiosensitizes non–small cell lung cancer and reduces radiation-induced pulmonary fibrosis.
https://insight.jci.org/articles/view/146334
Primary preclinical cancer study

[3] Bourgeois et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
https://www.nature.com/articles/s41467-025-60844-9
Primary structural and biophysical study

[4] Cleara Biotech. Company-reported CL04183 / CL04177 development.
https://www.clearabiotech.com/
Company development statement

[5] Sarlis et al. WIN 2026, abstract 40. Understanding and targeting p53 impairment in advanced cancer - Transitioning into the clinic. Printed p.152 (PDF p.155).
https://winconsortium.org/files/WIN_SYMPOSIUM_2026_PROGRAM_BOOK_V6.0_2026_10_26_FINAL_.pdf
Company-authored conference abstract

[6] ClinicalTrials.gov. Named-term registry searches, November 5, 2026.
https://clinicaltrials.gov/search?term=FOXO4-DRI
Dated registry search; not proof of universal absence

EVIDENCE LIMITATIONS
Cell and mouse findings do not establish human cancer-treatment efficacy or safety.
Mouse tumor effects were context-specific comparisons with radiation and senescence-like fibroblasts; no claim of reliable standalone tumor shrinkage or recurrence prevention.
Molecular binding is not therapeutic proof. The 2025 paper discloses Cleara funding and author equity/patent interests.
CL04183 is distinct from original FOXO4-DRI; a designed trial does not mean recruitment or completion.
ClinicalTrials.gov searches dated November 5, 2026 checked FOXO4-DRI, FOXO4 DRI, Proxofim, CL04183, CL-04183, CL04177 and Cleara; all returned zero. This is not proof no human use or unregistered study exists.
No independently verified FDA approval/nonapproval claim is made. No safe human dose is established by these studies.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Original user-requested cancer evidence explainer; supplied screenshots used as topic references, not primary evidence.